Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000186875 | SCV000240446 | uncertain significance | not provided | 2018-08-06 | criteria provided, single submitter | clinical testing | p.Pro375Ala (CCC>GCC): c.1123 C>G in exon 6 of the CHRNA2 gene (NM_000742.3). The Pro375Ala missense change has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. This variant alters a position that is not highly conserved, and it does not occur within the transmembrane region of the protein where pathogenic missense mutations have been identified in association with epilepsy (Steinlein et al., 2010). Although Proline and Alanine are both uncharged, non-polar amino acids, the loss of a bulky Proline residue may alter the secondary structure of the protein. Multiple in silico algorithms predict that Pro375Ala is damaging to the structure/function of the protein. The variant is found in EPILEPSY panel(s). |
| Illumina Laboratory Services, |
RCV001159829 | SCV001321572 | likely benign | Autosomal dominant nocturnal frontal lobe epilepsy 4 | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
| Labcorp Genetics |
RCV001852441 | SCV002141267 | likely benign | Autosomal dominant nocturnal frontal lobe epilepsy | 2023-11-25 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV003243007 | SCV003950943 | uncertain significance | Inborn genetic diseases | 2023-05-31 | criteria provided, single submitter | clinical testing | The c.1123C>G (p.P375A) alteration is located in exon 6 (coding exon 5) of the CHRNA2 gene. This alteration results from a C to G substitution at nucleotide position 1123, causing the proline (P) at amino acid position 375 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |